Company Profile

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Companyâ€™s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.

Employees

Sector

Biotechnology & Medical Research

More about the company

01/07/25	Oncternal Therapeutics, Inc. Appoints Craig R. Jalbert as CEO	CI
01/07/25	Oncternal Therapeutics, Inc. Announces Management Changes	CI
05/12/24	Oncternal Therapeutics, Inc.(NasdaqCM:ONCT) dropped from S&P TMI Index	CI
02/12/24	Oncternal Therapeutics, Inc.(NasdaqCM:ONCT) dropped from NASDAQ Composite Index	CI
25/11/24	Top Premarket Decliners	MT
07/11/24	Oncternal Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
23/10/24	Oncternal Therapeutics Continues to Explore Strategic Alternatives	CI
22/10/24	Oncternal Therapeutics, Inc. Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	CI
12/09/24	Oncternal Therapeutics, Inc. Announces Discontinue Its Clinical Trials Evaluating ONCT-534	CI
12/09/24	Oncternal Therapeutics, Inc. Announces Workforce Reduction	CI
12/09/24	Oncternal Therapeutics, Inc. Announces Cessation of Salim Yazji as Chief Medical Officer, Effective as of October 1, 2024	CI
12/09/24	Sector Update: Health Care Stocks Rise in Thursday Trading	MT
12/09/24	Oncternal Therapeutics Announces Exploration of Strategic Alternatives	CI

12/09/24	Brookline Capital Downgrades Oncternal Therapeutics to Hold From Buy	MT
15/04/24	HC Wainwright Cuts Oncternal Therapeutics' Price Target to $28 From $30, Keeps Buy Rating	MT
04/12/23	Brookline Capital Upgrades Oncternal Therapeutics to Buy From Hold, Price Target is $2	MT
18/09/23	HC Wainwright Upgrades Oncternal Therapeutics to Buy From Neutral, Price Target is $2	MT
04/04/23	Maxim Downgrades Oncternal Therapeutics to Hold From Buy	MT

08/03/25	Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC	AQ
25/11/24	Oncternal Therapeutics : Failure to Satisfy Listing Rule Form 8 K	PU
22/10/24	Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	AQ
12/09/24	Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives	AQ
08/08/24	Oncternal Therapeutics: Q2 Earnings Snapshot	AQ

3 years	0.53	13.14
5 years	0.53	89.8
10 years	0.53	211.2

Manager	Title	Age	Since
Richard Vincent DFI	Director of Finance/CFO	63	01/04/2017
Yisrael Katz CTO	Chief Tech/Sci/R&D Officer	-	01/07/2023
Rajesh Krishnan CTO	Chief Tech/Sci/R&D Officer	53	-

Oncternal Therapeutics, Inc. Stock

Stocks

ONCT

US68236P2065

Biotechnology & Medical Research

Latest news: Oncternal Therapeutics, Inc.

Analysts' recommendations: Oncternal Therapeutics, Inc.

Press Releases: Oncternal Therapeutics, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Oncternal Therapeutics, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Director	Title	Age	Since
Dan Kisner BRD	Director/Board Member	79	07/06/2019
William LaRue BRD	Director/Board Member	75	01/12/2017
Xin Nakanishi BRD	Director/Board Member	64	01/11/2018

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/20/24 A	Michael Carter	Free	Director	2,200	0.0743%
6/20/24 A	Charles Theuer	Free	Director	2,200	0.0743%
6/20/24 A	Dan Kisner	Free	Director	2,200	0.0743%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ONCTERNAL THERAPEUTICS, INC.	-24.11%	-.--%	-	-	1.56M
WUXI APPTEC CO., LTD.	+2.41%	+0.29%	+42.02%	+71.57%	64.69B
ARGENX SE	-0.15%	+7.50%	+11.01%	+73.48%	54.78B
LONZA GROUP AG	+0.57%	+4.60%	+10.07%	+92.86%	53.49B
IQVIA HOLDINGS INC.	+0.37%	+4.67%	+27.03%	+52.07%	45.98B
BEONE MEDICINES AG	-1.21%	+2.32%	+21.80%	+123.81%	42.94B
REVOLUTION MEDICINES, INC.	-0.37%	+5.07%	+249.91%	+918.74%	40.08B
CELLTRION, INC.	+0.05%	+0.21%	+18.26%	+58.53%	33.52B
GENMAB A/S	-0.38%	+5.68%	+36.43%	+27.54%	23.67B
WUXI BIOLOGICS (CAYMAN) INC.	+1.19%	-4.98%	+29.01%	-0.65%	23.97B
Average	-2.16%	+2.41%	+49.51%	+157.55%	42.57B
Weighted average by Cap.	+0.39%	+2.73%	+47.57%	+158.58%